Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 4,992

The DOI matches its Crossref record; 272 of the 272 references it cites were found in a registry or an index.

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis

Open access
Meijer, Laurent, Nelson, Deborah J., Riazanski, Vladimir, Gabdoulkhakova, Aida G., Hery-Arnaud, Geneviève, Le Berre, Rozenn, Loaëc, Nadège, Oumata, Nassima, Galons, Hervé, Nowak, Emmanuel, Gueganton, Laetitia, Dorothée, Guillaume, Prochazkova, Michaela, Hall, Bradford, Kulkarni, Ashok B., Gray, Robert D., Rossi, Adriano G., Witko-Sarsat, Véronique, Norez, Caroline, Becq, Frédéric, Ravel, Denis, Mottier, Dominique, Rault, Gilles · 2016 · Journal of Innate Immunity

Abstract

(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammatory lymphocytes and reduced production of various interleukins, notably IL-17A) contribute to the resolution of inflammation and restoration of innate immunity, and (4) roscovitine displays analgesic properties in animal pain models. The fact that (R)-roscovitine has undergone extensive preclinical safety/pharmacology studies, and phase I and II clinical trials in cancer patients, encourages its repurposing as a CF drug candidate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000444256

Cites

272 of 272 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–272 of 272

Research works printed but not linked: 27

  1. 10.1159/000350215 · doi:10.1159/000350215
  2. 10.1021/ar0201198 · doi:10.1021/ar0201198
  3. 10.1097/01.ASN.0000124672.41036.F4 · doi:10.1097/01.asn.0000124672.41036.f4
  4. 10.1111/nyas.12001 · doi:10.1111/nyas.12001
  5. 10.1096/fj.03-0035fje · doi:10.1096/fj.03-0035fje
  6. 10.1158/1078-0432.CCR-08-1748 · doi:10.1158/1078-0432.ccr-08-1748
  7. 10.1530/REP-07-0069 · doi:10.1530/rep-07-0069
  8. 10.4161/cbt.4.1.1462 · doi:10.4161/cbt.4.1.1462
  9. 10.2174/156802611795589601 · doi:10.2174/156802611795589601
  10. 10.2174/1568026611313030008 · doi:10.2174/1568026611313030008
  11. 10.1111/bph.12723 · doi:10.1111/bph.12723
  12. 10.1042/BJ20021975 · doi:10.1042/bj20021975
  13. 10.2174/138920111793937943 · doi:10.2174/138920111793937943
  14. 10.1177/1947601910369817 · DOI
  15. 10.1016/j.jcf.2012.07.003 · DOI · Paper page
  16. 10.1159/000350215 · doi:10.1159/000350215
  17. 10.1136/thx.2008.096834 · doi:10.1136/thx.2008.096834
  18. 10.1159/000295791 · doi:10.1159/000295791
  19. 10.1136/thx.49.5.496 · doi:10.1136/thx.49.5.496
  20. 10.1111/imm.12416 · DOI
  21. 10.3109/08820139.2014.888447 · doi:10.3109/08820139.2014.888447
  22. 10.1371/journal.pone.0081154 · DOI
  23. 10.1097/MEG.0000000000000011 · doi:10.1097/meg.0000000000000011
  24. 10.1007/s10072-014-1713-9 · doi:10.1007/s10072-014-1713-9
  25. 10.1016/j.brainresbull.2014.04.008 · doi:10.1016/j.brainresbull.2014.04.008
  26. 10.1111/j.1745-7254.2005.00007.x · doi:10.1111/j.1745-7254.2005.00007.x
  27. 10.2174/1574892810666150617112230 · doi:10.2174/1574892810666150617112230

Cited by

See all 4,992

Metadata

Authors
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Gueganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A. B., Gray, R. D., Rossi, A. G., Witko-Sarsat, V., Norez, C., Becq, F., Ravel, D., Mottier, D., & Rault, G.
Venue
Journal of Innate Immunity
Publisher
S. Karger AG
Published
2016
Volume
8
Issue
4
Pages
330-349
ISSN
  • 1662-811X (ISSN-L)
  • 1662-8128
OpenAlex
W2301131921
Cited by
4,992
References
272
FWCI
438.81
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.